Drug Interaction Between Ondansetron and Promethazine

Primary Cardiac Concern: QT Prolongation

The American College of Cardiology and other guideline societies recommend that ondansetron and promethazine can be safely used together for antiemetic therapy, but both drugs independently prolong the QT interval, creating an additive cardiac risk that requires ECG monitoring and electrolyte correction before initiation, particularly in patients with pre-existing cardiac conditions or those taking other QT-prolonging medications 1, 2, 3
The National Comprehensive Cancer Network specifically warns that combining ondansetron with other medications creates exacerbated QT prolongation risk, with a mean increase of QT interval prolongation 2, 3
Promethazine is listed among antiemetics that require caution due to sedative effects and potential cardiac risks, according to the European Society of Cardiology 4, 5

The American Heart Association recommends obtaining baseline ECG to assess QT interval, especially if the patient has cardiac risk factors, before initiating ondansetron and promethazine together 1, 6
The National Comprehensive Cancer Network advises checking and correcting electrolyte abnormalities, particularly potassium and magnesium, as these enhance cardiac toxicity 6
The American College of Cardiology suggests reviewing the complete medication list for other QT-prolonging agents, such as fluoroquinolones, macrolides, azole antifungals, and certain chemotherapies, to minimize the risk of QT interval prolongation 1, 2, 3

The European Society of Gastroenterology warns that promethazine can cause severe tissue injury with inadvertent perivascular extravasation, intra-arterial injection, or perineuronal infiltration, leading to tissue necrosis and gangrene 5
The American Society of Health-System Pharmacists recommends infusing promethazine slowly (≤25 mg/min) to minimize hypotension risk 5
The National Comprehensive Cancer Network notes that promethazine can cause extrapyramidal effects, ranging from restlessness to oculogyric crises, though less common than with metoclopramide 5, 7

The European Journal of Heart Failure suggests using the lowest effective doses of promethazine (6.25-12.5 mg IV) and ondansetron (4 mg IV) to minimize cardiac risk, with consideration of adding dexamethasone for synergistic antiemetic effect without additional QT concerns 4, 6

The American Heart Association recommends instructing patients to immediately report palpitations, syncope, or changes in heart rate indicating potential arrhythmia, as well as signs of tissue injury at the IV site, excessive sedation, or respiratory depression 5, 6
The National Comprehensive Cancer Network advises monitoring for extrapyramidal symptoms, such as muscle stiffness, tremors, or involuntary movements, when using promethazine 5, 7

The American College of Cardiology suggests considering metoclopramide or prochlorperazine as first-line alternatives when the combined cardiac risk of ondansetron and promethazine is unacceptable, though monitoring for akathisia is necessary 6
The National Comprehensive Cancer Network recommends olanzapine as a particularly helpful alternative in specific situations, such as bowel obstruction, without QT concerns 6
The American Society of Clinical Oncology advises considering non-pharmacological approaches for nausea management and using antiemetics targeting different mechanisms sequentially rather than simultaneously 7, 8